# To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

> **NCT05404529** · PHASE1 · COMPLETED · sponsor: **Cerevel Therapeutics, LLC** · enrollment: 32 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Tavapadon

## Key facts

- **NCT ID:** NCT05404529
- **Lead sponsor:** Cerevel Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-29
- **Primary completion:** 2023-01-24
- **Final completion:** 2023-01-24
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05404529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05404529, "To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05404529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*